clinical trial · NCT03897881
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
ModernaTX, Inc.·phase2·active not recruiting·n = 267
MelanomamRNA-4157Pembrolizumab
brief summary
The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of cutaneous melanoma and a high risk of recurrence.
started
Jul 18, 2019
primary completion
Nov 30, 2032
completion
Nov 30, 2032
last updated
Dec 3, 2025
official title
A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (KEYNOTE- 942)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol